GlassScriptPhysician profile
Saher Aslam
NPI 1174180053
$966.24
in general payments reported to CMS, 2019-2025
19 companies · $966 in 2025
The $966 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $949 · Education: $17.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $948.67 |
| Education | $17.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $150.00 | 2025 | Nxstage System One |
| Bayer Healthcare Pharmaceuticals INC. | $114.71 | 2025 | |
| Vantive US Healthcare LLC | $104.90 | 2025 | |
| Travere Therapeutics, INC. | $84.14 | 2025 | Filspari |
| Amgen INC. | $72.15 | 2025 | Krystexxa, Tavneos |
| Alnylam Pharmaceuticals INC. | $64.00 | 2025 | Givlaari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.66 | 2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $47.25 | 2025 | Jynarque |
| Akebia Therapeutics INC | $45.93 | 2025 | Vafseo |
| Novartis Pharmaceuticals Corporation | $40.60 | 2025 | |
| Genzyme Corporation | $31.71 | 2025 | |
| Aurinia Pharma U.S., INC. | $27.38 | 2025 | Lupkynis |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $26.89 | 2025 | |
| Renalytix Ai, INC. | $23.85 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Apellis Pharmaceuticals, INC. | $20.00 | 2025 | Empaveli |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $16.71 | 2025 | Ibsrela |
| Opko Pharmaceuticals, LLC | $15.52 | 2025 | Rayaldee |
| Calliditas Therapeutics US INC. | $15.15 | 2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $14.69 | 2025 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saher Aslam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.